MEET YOUR NEW AI CLINICAL ASSISTANT /// GET EARLY ACCESS
COMPREHENSIVE AND COMPLEMENTARY SEQUENCING
We offer worldwide access to our comprehensive genomic profiling services and data-driven solutions to help inform patient care and advance precision oncology decisions.
Download our case studies to see how we support sequencing for research, clinical trials, and sponsored testing.
Tempus xF
xF+: Targeted Panel of 523 genes (available on a limited basis)
xF: Targeted Panel of 105 genes
Liquid Biopsy Test
Tempus xG (Powered by GeneDx)
88-gene and 52-gene germline panels
xG+ (extended hereditary cancers)
xG (common hereditary cancers)
DNA + RNA Whole Transcriptome Sequencing
29% more patients were identified with a unique clinically actionable fusion matched to a targeted therapy, compared to DNA sequencing alone.1
Solid Tumor and Normal Matched DNA Sequencing
28% reduction in somatic false-positive calls, improving accuracy compared to tumor-only analysis.2
Incidental Germline Findings
7% of patients were found to harbor pathogenic or likely pathogenic germline variants across multiple cancer types and are indicated for confirmatory germline testing, per high risk assessment guidelines.3,4
Concurrent Solid Tumor and Liquid Biopsy Testing
9% of patients had unique actionable variants found in liquid biopsy that were not detected in solid tumor alone.5
Clinical Data Integration
96% of patients matched to a clinical trial when clinical data was combined with Tempus NGS.2
Automatic Conversion Option
In the event of insufficient tumor tissue, convert to liquid biopsy testing for rapid genomic results.
Algorithmic Tests
We provide advanced patient insights without the need for additional tissue.
Our online Hub allows you secure, fast, reliable access to patient report status and results. View interactive and in-depth next-generation sequencing results in the context of a patient’s clinical history, filterable treatment applications and clinical trials, and PDFs of all Tempus reports.
You will also have access to our near real-time support tool that connects you with up-to-date treatment options and relevant insights derived from real-world clinical evidence across millions of de-identified patient records, our vast library of molecular profiling data, and our advanced analytics and machine-learning algorithms.
Download the Tempus mobile app.
After processing your entire order, we produce an order summary highlighting all key findings from the xT and xF tests along with additional tests like HRD and TO, including actionable treatments, microsatellite instability (MSI) status, and tumor mutational burden (TMB) that can be quickly translated into cancer patient care.
Our reports are also embedded with Tempus Insights, patient-specific insights derived from real-world evidence to empower physicians with the necessary data to improve patient care.
Get in touch to learn more.
Tempus is the first genomic sequencing company to incorporate both Memorial Sloan Kettering Cancer Center’s OncoKB and NCCN Content into smart clinical reports. MSK OncoKB & NCCN are two of the most robust oncology databases in the world. With the integration of these trusted sources, you can:
With a dedicated team of integration experts, we offer a fully interoperable solution for clinical ordering and returning results back into an institution’s health IT systems. We can transform our report into discrete genomic data that can be loaded directly into your system(s) in industry standard HL7 format. In addition, we collaborate with partners to offer a fully interoperable structured result file format which can be parsed and loaded into an institution’s data ecosystem to power their precision medicine program.
To ease the clinical ordering workflow, we support the automation of appropriate and secure data sharing to power your precision medicine program with Tempus clinical support and advanced analytics. If you have already ordered Tempus through paper or online methods, we can historically backfill prior results into your system(s).
We understand the power of analytics and the positive impact it has on clinical support.
Contact us today.The Tempus Sequencing Lab
We operate CAP-accredited, CLIA-certified robotic sequencing labs in Chicago, Atlanta, and Raleigh with automated bioinformatics and variant classification reporting. Sequencing is completed within 8–10 days on average of receiving patient samples.
Download our lab overview
AS PUBLISHED IN NATURE BIOTECHNOLOGY JOURNAL
“Extensive molecular profiling combined with clinical data identifies targeted therapies and clinical trials […] and paired tumor/normal plus transcriptome sequencing outperforms tumor-only DNA panel testing.”
Learn more about the xT 500 Publication in Nature Biotechnology
Combined DNA and RNA sequencing using Tempus|xT increased the high level therapy matching rate to 43.4% of patients.
Follow-Up Testing Covered Under Tempus Financial Assistance*
Any US-based patient who receives Tempus testing may apply for our Financial Assistance Program. If approved, the program covers all medically necessary xT (solid), xF (liquid) and xG (hereditary) testing within 18 months of approval.
*Tempus testing is always conducted based on the medical judgment of an ordering physician.This is the future of healthcare.
648 gene panel by DNA sequencing + whole transcriptome RNA sequencing with reporting of clinically relevant fusions and altered splicing events
Enriched for clinically relevant genes and genes of emerging clinical relevance
Immunotherapy Metrics: MSI Status, Tumor Mutational Burden (TMB)
IHC Options: Mismatch Repair (MMR), PD-L1 (22C3, SP142, SP263, and 28-8 clones)
Available Add-on Tests: Tumor Origin (TO), Homologous Recombination Deficiency (HRD), DPYD, and UGT1A1
*Includes promoter region; **Genes in which incidental germline findings are reported
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Liquid Biopsy Test
xF+: 523-gene DNA Panel
Targeted panel designed to detect actionable oncologic targets in plasma. Available on a limited basis
Immunotherapy Metrics: MSI-High Status, Blood TMB (bTMB)
Download xF+ Gene Panel
Download xF+ Validation Summary
xF: 105-gene DNA panel
Targeted panel designed to detect actionable oncologic targets in plasma
Immunotherapy Metrics: MSI-High Status
Download xF Gene Panel
Download xF Validation Summary
A
B
C
D
E
F
G
H
I
J
K
M
N
P
R
S
T
U
V
Targeted Panels of 88 (xG+) & 52 (xG) genes
Providing risk-assessment for hereditary cancer syndromes for patients and their families
A
B
C
D
E
F
G
H
K
L
M
N
P
R
S
T
V
W